晚期非小细胞肺癌二线治疗进展.pdfVIP

4 中国肺癌杂志2008 年2 月第11 卷第1 期 Chin J Lung Cancer, February 2008, Vol.11, No.1 窑第十二届世界肺癌大会专题窑 晚期非小细胞肺癌的二线治疗进展 张力 揖摘要铱 晚期非小细胞肺癌一线化疗后仅能有一个较短暂的疾病缓解期袁 绝大部分患者需要进行二线治 疗遥 目前推荐的二线治疗药物主要是多西紫杉醇尧培美曲赛和EGFR-TKIs遥多西紫杉醇最先确立其二线治疗的 地位遥培美曲赛通过一项与多西紫杉醇进行随机对照的III 期研究批准用于晚期NSCLC 二线治疗遥虽然培美曲 赛毒性很轻 袁但进一步的临床研究并没有发现高剂量对患者生存有益遥 EGFR-TKIs 靶向治疗是目前研究的 热点遥 吉非替尼和厄洛替尼单药二线治疗具有较好的疗效遥 吉非替尼与传统化疗对照的研究表明袁其疗效不差 于多西紫杉醇袁且毒性较化疗轻 遥厄洛替尼与化疗对照的研究正在进行遥其 一些药物不断出现袁显示了其在 二线治疗的 用袁例如口服拓扑替肯和长春氟宁与多西紫杉醇均具有相似的疗效遥 揖关键词铱 肺肿瘤 二线化疗 多西紫杉醇培美曲赛 表皮生长因子酪氨酸激酶抑制剂 揖中图分类号铱 R734.2 DOI: 10.3779/j.issn.1009-3419.2008.01.002 Advance of second-line chemotherapy in advanced non-small cell lung cancer De partment of Medical Oncology: Cance r Ce nte r of Sun Y at-Se n Unive rs ity, Guangz hou, 510060, China Corres ponding author:ZHA NG Li, E-mail: zhangli6@mail.sysu.edu.cn 揖Abstract铱 There is a temporal disease -free period after 1st line chemotherapy in advanced non -small cell lung cancer (NSCLC), most of patients need 2nd line chemotherapy. The recommended drugs in the 2nd line were docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Single docetaxel is the established therapy for second -line treatment of NSCLC.Pemetexem was validated its indication in the 2nd line in advanced NSCLC through a phase III randomised clinical trial which was compared with docetaxel. Although there were little toxicity, the further research can 爷t find the survival benefit in high dose pemetrexed. EGFR-TKIs target therapy